Nov. 30, 2012
AMRI (NASDAQ: AMRI) announced today that as a next step in its SMARTSOURCING™ strategy it has taken further actions to expand and better integrate its
biology services with its total drug discovery service platform.
As a result of shifting market preferences related to integrated drug discovery activities, AMRI will further optimize its location footprint by closing its
site. The site's biology capabilities will transition to AMRI's fully integrated discovery location in
and certain analytical capabilities will consolidate into AMRI's analytical quality group in
location employs 24 people.
AMRI estimates that it will incur certain one-time cash and non-cash charges related to the reduction in force and other transition activities of approximately
, of which approximately
in non-cash charges will be incurred in the fourth quarter. AMRI expects the actions announced today will generate annual savings of approximately
. Further details will be available in a Form 8-K filing.
"By further aligning and integrating our global biology services, AMRI continues to address and anticipate changes in the marketplace, strengthening our position as a premier provider of integrated drug discovery services," said Thomas E. D'Ambra, Ph.D., AMRI's Chairman, President and Chief Executive Officer. "Already our SMARTSOURCING™ initiatives are proving effective as evidenced by expanded contract services opportunities; this next move provides us the potential to better pursue these opportunities as we enter 2013. We will continue to focus on improving our cost structure and capabilities in order to build stronger and long-term relationships with existing and new customers. AMRI has been known as a top chemistry service company for many years, and this will help the marketplace to also integrate our top-level biology offerings."